Changing practices in the surgical management of hyperparathyroidism – A 10-year review

The surgical management of primary hyperparathyroidism: an updated review

Patients with primary hyperparathyroidism often present clinically asymptomatic with various biochemical compositions of serum calcium, parathyroid hormone, vitamin D and urinary calcium. Understanding the subtle differences in clinical and biochemical presentations is key for timely diagnosis and referral to an experienced parathyroid surgeon. Surgery remains the only option for cure of primary hyperparathyroidism, which now favors a directed parathyroidectomy with intra-operative adjuncts. However it is important to understand and revise the surgical approach for patients with hereditary conditions or nonlocalizing studies. Revised guidelines from the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism in 2013 and the American Association of Endocrine Surgeons in 2016 are reviewed in this paper for an updated review of this condition.

A 20-year study on 190 patients with primary hyperparathyroidism in a developing country: Turkey experience

The aim of this study was to present our 20-year experience regarding primary hyperparathyroidism (PHPT). PHPT patients who underwent parathyroidectomy in our clinic were reviewed retrospectively. There were 190 PHPT patients, of whom 137 were asymptomatic (72%). The mean serum calcium at the time of diagnosis was 11.9 ± 2.2 mg/dL. The mean parathyroid hormone (PTH) level was 467 ± 78 pg/mL. Ultrasonography (USG) identified all abnormal glands accurately (82.6%) and Technetium-99m sestamibi scintigraphy (MIBI) was used in 89.4% of the patients and magnetic resonance imaging (MRI) in 61%. The common use of USG and MIBI detected 92% of the lesions. Bilateral neck exploration (BNE) was performed in 12.2% of the patients and focused unilateral neck exploration (FUNE) in the remaining 87.8%. Surgical intervention was unsuccessful in 1 patient (0.5%). The conversion ratio from FUNE to BNE was 5.2%. The mean operation time and mean hospital stay decreased significantly in patients with FUNE. Pathologic examination revealed single adenoma in 93% of the patients. New imaging techniques result in the conversion of surgical treatments of PHPT. FUNE in parathyroidectomy performed by an experienced surgeon may provide successful treatment rates.

Surgical management of primary hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a common endocrine disorder in which the inappropriate elevation in serum parathyroid hormone level results in hypercalcemia. Most cases are caused by a single adenomatous parathyroid gland and less than 15% are caused by multiglandular disease. The incidence of PHPT appears to be increasing. More patients are being identified earlier and often before symptoms develop. Parathyroidectomy is the only definitive management; with it, the patient can achieve biochemical homeostasis and symptom relief, and sequelae are prevented. Even for asymptomatic patients with PHPT, there is a growing trend to recommend early surgical intervention. Controversy continues regarding the role of and reliance on various technologies, such as preoperative localization imaging, intraoperative parathyroid hormone level measurements, and minimally invasive surgery. Although both traditional bilateral 4-gland exploration and targeted approaches are accepted surgical techniques, there is a growing trend in unilateral targeted operations often using these technologies. Regardless of surgical approach, the expected success rate is greater than 95%. This article provides an overview of the contemporary surgical management of PHPT.